- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dabrafenib/Trametinib Combo Improves OS Versus Vemurafenib in Advanced Melanoma
September 27th 2015, 2:01pm
The combination of dabrafenib plus trametinib improved overall survival by 7.6 months compared with single-agent vemurafenib in patients with unresectable or metastatic BRAFV600E/K-mutant melanoma.
T-VEC/Pembrolizumab Combination Demonstrates Safety in Melanoma
September 27th 2015, 11:57am
The combination of the attenuated oncolytic virus talimogene laherparepvec and the immune checkpoint inhibitor pembrolizumab for unresectable melanoma has passed an early safety evaluation.
Atezolizumab Provides Viable Treatment Option in Metastatic Urothelial Carcinoma
September 27th 2015, 10:49am
Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.
Two Pivotal Studies Show Efficacy of Atezolizumab in PD-L1-Positive NSCLC
September 27th 2015, 10:20am
Inhibition of PD-L1 with atezolizumab demonstrated significant clinical efficacy as monotherapy in patients with advanced non-small cell lung cancer.
Dr. Nghiem on Pembrolizumab for Advanced Merkel Cell Carcinoma
September 27th 2015, 9:07am
Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine discusses a phase II trial investigating the PD-1 blockade pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).
Nivolumab Before Ipilimumab Has Greater Efficacy, Similar AEs
September 27th 2015, 9:04am
Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.
Dr. Toni Choueiri on Cabozantinib Versus Everolimus in Renal Cell Carcinoma
September 27th 2015, 8:48am
Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).
Dr. Hisham Mehanna on Quality of Life Differences in Head and Neck Squamous Cell Cancer
September 26th 2015, 2:39pm
Hisham Mehanna, MBChB, PhD, Chair, Head and Neck Surgery, Director, Institute of Head and Neck Studies and Education at University of Birmingham, discusses differences in the quality of life (QoL) and functional outcomes of treatment between HPV-positive and HPV-negative head and neck squamous cell cancer patients (HNSCC).
Most Brain Metastases Have Actionable Mutations Not Found in Primary Tumor
September 26th 2015, 2:32pm
More than half of brain metastases harbored clinically actionable genetic alterations that were distinct from those associated with the primary tumor.
Dr. Philippe Ruszniewski on NETTER-1 Study Results
September 26th 2015, 2:31pm
Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase 3 NETTER-1 study.
Targeted Radionuclide Improves PFS Over Octreotide LAR in Midgut NETs
September 26th 2015, 2:07pm
Treatment with the novel peptide receptor radionuclide therapy Lutathera significantly increased progression-free survival over octreotide LAR in patients with advanced midgut neuroendocrine tumors.
Everolimus May Be New Standard of Care in Advanced Lung, GI NETs
September 26th 2015, 1:56pm
Treatment with everolimus was associated with a 52% improvement in median progression-free survival compared with placebo in patients with advanced lung and gastrointestinal neuroendocrine tumors.
Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma
September 26th 2015, 9:14am
More than a fifth of patients with previously treated metastatic nasopharyngeal carcinoma showed a measurable response when treated with the immune checkpoint inhibitor pembrolizumab.
Trabectedin OS Data Unclear in Phase III Sarcoma Study
September 26th 2015, 8:52am
The final analysis of phase III data for trabectedin were consistent with interim results by showing a lack of improvement for the primary endpoint of overall survival in patients with advanced soft tissue sarcoma.
Nivolumab Extends Survival in Advanced Renal Cell Carcinoma
September 25th 2015, 2:08pm
Nivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.
Second-Line Cabozantinib Improves PFS in Advanced RCC
September 25th 2015, 1:56pm
Second-line treatment with cabozantinib reduced the risk of progression or death by 42% compared with everolimus in patients with advanced renal cell carcinoma.
Osimertinib Produces High Response Rate in EGFR T790M-Mutant NSCLC
September 10th 2015, 4:03pm
World Conference on Lung Cancer
The third-generation TKI osimertinib (AZD9291) showed a 71% objective response rate in patients with EGFR T790M-mutant non–small cell lung cancer following resistance to frontline anti-EGFR therapy.
Deep Sequencing Reveals Possible Primary Resistance Mechanism in EGFR-Mutant NSCLC
September 9th 2015, 3:03pm
World Conference on Lung Cancer
Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.
Cetuximab Improves Survival in EGFR-Positive Squamous NSCLC
September 9th 2015, 2:41pm
World Conference on Lung Cancer
The addition of cetuximab (Erbitux) to chemotherapy reduced the risk of death by 44% for patients with advanced squamous non–small cell lung cancer whose tumors test positive for EGFR gene amplification.
Survival Not Improved by Adjuvant Bevacizumab in NSCLC
September 9th 2015, 2:36pm
World Conference on Lung Cancer
The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.